News

August 13, 2018

A FACES-Inspired Clinical Trial – Engage Therapeutics CEO, Greg Mayes

Read the article by Greg Mayes, Engage Therapeutics CEO, in FACES Annual Newsletter 2018: A FACES-Inspired Clinical Trial to Investigate the Efficacy and Clinical Usability of […]
June 27, 2018

Engage Therapeutics CEO, Greg Mayes, makes opening remarks to Clinical Investigators at the StATES Investigator Meeting. New Orleans, LA – June 8, 2018

Engage Therapeutics CEO, Greg Mayes, makes opening remarks to Clinical Investigators at the StATES Investigator Meeting. New Orleans, LA – June 8, 2018
May 18, 2018

STACCATO® ALPRAZOLAM

G. Mayes CEO, Engage Therapeutics, Summit, NJ, United States Staccato Alprazolam (STAP-001) is a single-use, hand-held, drug-device combination product that provides rapid systemic delivery by inhalation […]
April 30, 2018

Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato® Alprazolam

Peachtree BioResearch Solutions to Execute Multi-Center Trial SUMMIT, N.J. – April XX, 2018 – Engage Therapeutics, Inc., today announced dosing of the first patient in its […]
April 20, 2018

Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy

SUMMIT, N.J., Sep. 27, 2017 – Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced […]